Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

SIBUTRAMINE HYDROCHLORIDE

Unique Identifier:SPE01505210
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:289.094 g/mol
X log p:8.664  (online calculus)
Lipinksi Failures1
TPSA3.24
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:1
Rotatable Bond Count:5
Canonical Smiles:Cl.CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1
Source:synthetic
Therapeutics:anorexic, antidepressant, uptake inhibitor (5HT, norepinephrine, dopamine)
Generic_name:Sibutramine
Chemical_iupac_name:1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine
Drug_type:Approved Drug
Pharmgkb_id:PA451344
Kegg_compound_id:C07247
Drugbank_id:APRD00456
Melting_point:191-192 oC
H2o_solubility:2.9 mg/mL (in pH 5.2 water)
Logp:5.906
Cas_registry_number:106650-56-0
Drug_category:Appetite Depressants; Antidepressants; Anorexigenic Agents; Stimulants; ATC:A08AA10
Indication:For the treatment of obesity.
Pharmacology:Sibutramine is an orally administered agent for the treatment of obesity.
Sibutramine exerts its pharmacological actions predominantly via its secondary (M1)
and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent
inhibitor of serotonin and norepinephrine reuptake in vivo, but not in
vitro
. However, metabolites M1 and M2 inhibit the reuptake of these
neurotransmitters both in vitro and in vivo. In human brain tissue, M1
and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower
potency than for the reuptake inhibition of serotonin or norepinephrine.
Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic
actions. In addition, receptor binding profiles show that sibutramine, M1 and M2
have low affinity for serotonin (5-HT1, 5-HT1A,
5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3,
a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors.
These compounds also lack monoamine oxidase inhibitory activity in vitro and
in vivo.
Mechanism_of_action:Sibutramine produces its therapeutic effects by norepinephrine (NE), serotonin
reuptake (5-hydroxytryptamine, 5-HT) and dopamine reuptake inhibition. Sibutramine
and its major pharmacologically active metabolites (M1 and M2) do not act via
release of monoamines.
Organisms_affected:Humans and other mammals

Found: 205 nonactive as graph: single | with analogs 2 3 4 5 6 7 8 9 10  Next >> [205]
Species: 4932
Condition: AAT2
Replicates: 2
Raw OD Value: r im 0.7490±0.0039598
Normalized OD Score: sc h 1.0193±0.0213199
Z-Score: 1.0097±1.11028
p-Value: 0.447474
Z-Factor: -5.46852
Fitness Defect: 0.8041
Bioactivity Statement: Nonactive
Experimental Conditions
Library:SPECMTS3
Plate Number and Position:1|B8
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:23.30 Celcius
Date:2008-04-08 YYYY-MM-DD
Plate CH Control (+):0.039975±0.00102
Plate DMSO Control (-):0.7103±0.01415
Plate Z-Factor:0.9224
png
ps
pdf

DBLink | Rows returned: 82 Next >> 
5210 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine
64764 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine hydrochloride
64765 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine hydrate hydrochloride
667542 (1R)-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine
937011 (1S)-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine
4978638 [1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl-butyl]-dimethyl-azanium

internal high similarity DBLink | Rows returned: 0

active | Cluster 2147 | Additional Members: 1 | Rows returned: 0

Service provided by the Mike Tyers Laboratory